Drug-Device Combination Products Consultant in Mumbai
The medical device industry in Mumbai is one of the largest and most vibrant in India, with a wide range of products including surgical instruments, diagnostic equipment, implants, and disposables. Mumbai is a hub for medical device manufacturing and distribution, with numerous small and large companies operating in the region. The industry is supported by a skilled workforce, world-class infrastructure, and a favorable business environment, making it an attractive destination for investment.
Combination products are a unique category of medical products that combine two or more regulated components, including drugs, devices, and biological products. As a Drug Device Combination Products Consultant in Mumbai, we provide comprehensive guidance on combination products under 21 CFR 3.2 (e).
Types of Drug-Device Combination Products
- Pre-filled syringes
- Drug-eluting stents
- Inhalers
- Transdermal patches
- Implantable drug delivery systems
- Drug-device combination products for diagnostics
- Drug-device combination products for drug delivery systems
- Drug-device combination products for gene therapy
Drug-Device Combination Products Consultant in Mumbai?
Let’s have word about your next project
Benefits of Drug-Drug Combination Products
Despite the challenges, drug-device combination products offer many unique benefits over traditional drugs or devices alone, such as targeted therapy, improved drug delivery, and increased patient compliance. They represent an exciting and growing area of innovation in the healthcare industry, with the potential to improve patient outcomes and quality of life.
If you are looking for expert guidance in the development and regulation of drug-device combination products in Mumbai, Operon Strategist can help. Our team of experienced consultants offers a range of services. Contact us today to learn more.
FAQs
What is a drug-device combination product?
A drug-device combination product is a therapeutic system that combines a drug and a medical device into a single product or co-packaged solution intended for combined use.
How are combination products regulated in India?
In India, regulation depends on the product’s Primary Mode of Action (PMOA). The Central Drugs Standard Control Organization determines whether the product will follow drug regulations, medical device rules, or a hybrid compliance pathway.
What is Primary Mode of Action (PMOA)?
PMOA refers to the primary therapeutic action of the product. It determines whether the product will be regulated mainly as a drug or as a device, significantly impacting approval requirements and timelines.
Are combination products regulated differently by the US FDA?
Yes. The U.S. Food and Drug Administration assigns a lead center (CDER, CDRH, or CBER) based on PMOA and may require compliance with both drug and device GMP requirements.
How long does approval take for a drug-device combination product?
Approval timelines vary depending on classification, clinical data requirements, and regulatory pathway. In India, review is conducted by the Central Drugs Standard Control Organization, while in the US it depends on the pathway assigned by the U.S. Food and Drug Administration. Complete documentation and proper regulatory strategy help avoid delays.